[12] Patent
[11] Patent No.:GC0011374  
[45] Date of Publishing the Grant of the Patent: 31/Jul /2020                72/2020  
Number of the Decision to Grant the Patent:2020/171409
Date of the Decision to Grant the Patent:28/Jul/2020

[21] Application No.:GC 2015-29200

[22] Filing Date:8/4/2015

[30] Priority:

[33] State [32] Priority date [31] Priority No.
PCT
9/4/2014
PCT/CN2014/075011

[72] Inventors:1- Jinguang LIN،2- Xin LINGHU،3- Jeffrey STULTS،4- Hans IDING،5- Jing LI،6- Jianqian ZHANG

[73] Owner: GENENTECH, INC., 1 DNA Way, California 94080, South San Francisco, USA

[74] Agent: Abu-Gazaleh Intellectual Property L.L.C

  

 

  

[51]IPC:
Int. Cl.: A61K 31/506 (2006.01)

[56] Cited Documents:

-WO 2013/130976 A1 (ARRAY BIOPHARMA INC [US]; GENENTECH INC [US]; BLAKE JAMES F [US]; CHIC) 6 September 2013

-MU X Q ET AL: 11 New kinetic and thermodynamic approach of one-pot synthesis of chiral alcohol by
oxidoreductase from Candida parapsilosis 11 •
PROCESS BIOCHEMISTRY. ELSEVIER LTD. GB.
vo 1 • 46. no. 1.
1 January 2011

-IKEMOTO N ET AL: 11 Practical routes to the triarylsulfonyl chloride intermediate of a
@b11 3 adrenergic receptor agonist 11 •
TETRAHEDRON. ELSEVIER SCIENCE PUBLISHERS. AMSTERDAM. NL.
vo 1 • 59. no. 8.
17 February 2003

-NAOMI CHI FURUKAWA ET AL: 11 Preparation of pyridyl grignard reagents and cross coupling reactions with sulfoxides bearing azaheterocycles 11 •
TETRAHEDRON LETTERS.
vol. 28. no. 47.
1 January 1987

-RICHARD J BASTIN ET AL: 11 Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities . ORGANIC PROCESS RESEARCH AND DEVELOP. AMERICAN CHEMICAL SOCIETY. US.
vol. 4. no. 5. 19 July 2000


 
Examiner: PH. Sarah A. AlGrainies

[54] PROCESS FOR THE MANUFACTURING OF MEDICAMENTS
[57] Abstract: The present invention provides a process for the manufacture of a compound of formula VIIIa and salts forms of VIIIa where Rc is an aryl sulfonic acid
No. of claims: 22     No. of figures: 2


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.